Pharmacology department: pharmacologic approaches to abnormal blood lipids.
There are currently four classes of drugs available to treat dyslipidemia: niacin, bile acid-binding resins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, and fibric acid derivatives. Each acts at a unique point in a complex set of interrelated lipid metabolic pathways. The mechanism of action and adverse effects of these four classes are reviewed briefly. The efficacy of antioxidants and the importance of compliance issues are described.
Gylys
K H
KH
University of California Los Angeles School of Nursing, USA.
D000837:Anion Exchange Resins / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D011345:Fenofibrate / Q000627:therapeutic use; D015248:Gemfibrozil / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000451:nursing*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D009525:Niacin / Q000627:therapeutic use; D015399:Nursing Research; D010349:Patient Compliance
D000837:Anion Exchange Resins; D000975:Antioxidants; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D009525:Niacin; D015248:Gemfibrozil; D011345:Fenofibrate